Brent R. Stockwell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brent R. Stockwell has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Brian P. Kelley
2 shared publicationsDavid E. Root
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
2 shared publicationsAlexis A. Borisy
CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118, USA
1 shared publicationBP Kelley
1 shared publication- Curtis T. Keith
CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118
1 shared publication DE Root
1 shared publication
Latest Publications
- 1 January 2004
- Published by Springer Nature in Nature Biotechnology
- Vol. 22 (1) , 37-38
The biological magic behind the bullets.
- 1 January 2004
- Published by Springer Nature in Nature Biotechnology
- Vol. 22 (1) , 37-38
The biological magic behind the bullets.
- Open Access
- 1 December 2003
- Published by Elsevier in Cancer Cell
- Vol. 4 (6) , 419-420
Restoring functions of tumor suppressors with small molecules
- 1 December 2003
- Published by Elsevier in Cancer Cell
- Vol. 4 (6) , 419-420
Open AccessRestoring functions of tumor suppressors with small molecules
- 1 September 2003
- Published by Elsevier in Chemistry & Biology
- Vol. 10 (9) , 881-892
Biological Mechanism Profiling Using an Annotated Compound Library
- 1 September 2003
- Published by Elsevier in Chemistry & Biology
- Vol. 10 (9) , 881-892
Biological Mechanism Profiling Using an Annotated Compound Library
- Open Access
- 1 August 2003
- Published by Elsevier in SLAS Discovery
- Vol. 8 (4) , 393-398
Detecting Spatial Patterns in Biological Array Experiments
- 1 August 2003
- Published by Elsevier in SLAS Discovery
- Vol. 8 (4) , 393-398
Open AccessDetecting Spatial Patterns in Biological Array Experiments
- Top Cited Papers
- 10 June 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (13) , 7977-7982
Systematic discovery of multicomponent therapeutics
Multicomponent therapies, originating through deliberate mixing of drugs in a clinical setting, through happenstance, and through rational design, have a successful history in a number of areas of medicine, including cancer, infectious diseases, and CNS disorders. We have developed a high-throughput screening method for identifying effective combinations of therapeutic compounds. We report here that systematic screening of combinations of small molecules reveals unexpected interactions between compounds, presumably due to interactions between the pathways on which they act. Through systematic screening of ≈120,000 different two-component combinations of reference-listed drugs, we identified potential multicomponent therapeutics, including ( i ) fungistatic and analgesic agents that together generate fungicidal activity in drug-resistant Candida albicans , yet do not significantly affect human cells, ( ii ) glucocorticoid and antiplatelet agents that together suppress the production of tumor necrosis factor-α in human primary peripheral blood mononu-clear cells, and ( iii ) antipsychotic and antiprotozoal agents that do not exhibit significant antitumor activity alone, yet together prevent the growth of tumors in mice. Systematic combination screening may ultimately be useful for exploring the connectivity of biological pathways and, when performed with reference-listed drugs, may result in the discovery of new combination drug regimens.
- 10 June 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (13) , 7977-7982
Top Cited PapersSystematic discovery of multicomponent therapeutics
Multicomponent therapies, originating through deliberate mixing of drugs in a clinical setting, through happenstance, and through rational design, have a successful history in a number of areas of medicine, including cancer, infectious diseases, and CNS disorders. We have developed a high-throughput screening method for identifying effective combinations of therapeutic compounds. We report here that systematic screening of combinations of small molecules reveals unexpected interactions between compounds, presumably due to interactions between the pathways on which they act. Through systematic screening of ≈120,000 different two-component combinations of reference-listed drugs, we identified potential multicomponent therapeutics, including ( i ) fungistatic and analgesic agents that together generate fungicidal activity in drug-resistant Candida albicans , yet do not significantly affect human cells, ( ii ) glucocorticoid and antiplatelet agents that together suppress the production of tumor necrosis factor-α in human primary peripheral blood mononu-clear cells, and ( iii ) antipsychotic and antiprotozoal agents that do not exhibit significant antitumor activity alone, yet together prevent the growth of tumors in mice. Systematic combination screening may ultimately be useful for exploring the connectivity of biological pathways and, when performed with reference-listed drugs, may result in the discovery of new combination drug regimens.
- 1 May 2002
- Vol. 5 (3) , 355-360
Global analysis of large-scale chemical and biological experiments
Research in the life sciences is increasingly dominated by high-throughput data collection methods that benefit from a global approach to data analysis. Recent innovations that facilitate such comprehensive analyses are highlighted. Several developments enable the study of the relationships between newly derived experimental information, such as biological activity in chemical screens or gene expression studies, and prior information, such as physical descriptors for small molecules or functional annotation for genes. The way in which global analyses can be applied to both chemical screens and transcription profiling experiments using a set of common machine learning tools is discussed.
- 1 May 2002
- Vol. 5 (3) , 355-360
Global analysis of large-scale chemical and biological experiments
Research in the life sciences is increasingly dominated by high-throughput data collection methods that benefit from a global approach to data analysis. Recent innovations that facilitate such comprehensive analyses are highlighted. Several developments enable the study of the relationships between newly derived experimental information, such as biological activity in chemical screens or gene expression studies, and prior information, such as physical descriptors for small molecules or functional annotation for genes. The way in which global analyses can be applied to both chemical screens and transcription profiling experiments using a set of common machine learning tools is discussed.
- 1 November 2000
- Published by Elsevier in Trends in Biotechnology
- Vol. 18 (11) , 449-455
Frontiers in chemical genetics
- 1 November 2000
- Published by Elsevier in Trends in Biotechnology
- Vol. 18 (11) , 449-455
Frontiers in chemical genetics
- 1 November 2000
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 1 (2) , 116-125
Chemical genetics: ligand-based discovery of gene function
Chemical genetics is the study of gene-product function in a cellular or organismal context using exogenous ligands. In this approach, small molecules that bind directly to proteins are used to alter protein function, enabling a kinetic analysis of the in vivo consequences of these changes. Recent advances have strongly enhanced the power of exogenous ligands such that they can resemble genetic mutations in terms of their general applicability and target specificity. The growing sophistication of this approach raises the possibility of its application to any biological process.
- 1 November 2000
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 1 (2) , 116-125
Chemical genetics: ligand-based discovery of gene function
Chemical genetics is the study of gene-product function in a cellular or organismal context using exogenous ligands. In this approach, small molecules that bind directly to proteins are used to alter protein function, enabling a kinetic analysis of the in vivo consequences of these changes. Recent advances have strongly enhanced the power of exogenous ligands such that they can resemble genetic mutations in terms of their general applicability and target specificity. The growing sophistication of this approach raises the possibility of its application to any biological process.